Last month Antisense Therapeutics received formal written feedback from the US Food and Drug Administration (FDA) on its development plans for ATL1102 for non-ambulant patients with Duchenne muscular dystrophy (DMD). Since then, Non-Executive Director Charmaine Gittleson, the Ex Chief Medical Officer of CSL, has been made the new Chair as the company moves into late-stage clinical trials. The appointment of Charmaine Gittleson as the new Chair brings with it her experience in the rare drug industry and in particular her global drug development and product registration knowledge.
In this video Managing Director and CEO Mark Diamond discusses the key highlights of the quarterly results for Antisense Therapeutics and the timeframes moving forward as the company advances its drug development for the treatment of Duchennes Muscular Dystrophy.
Antisense Therapeutics is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development.
